Table 4: Primary and secondary outcomes based on HBP# and CBP## measured at end-point in 116 obese patients with type 2 diabetes mellitus.

Outcome

Patient status: HBP* at end-point in 116 obese patients

Patient status: CBP** at end-point in 116 obese patients

Hypertension

Normotension

Hazard ratio

P

Hypertension

Normotension

Hazard ratio

P

(n = 73)

(n = 43)

 (95% CI)

 

(n = 54)

(n = 62)

(95% CI)

Primary outcome

Death

20

5

0.4 (0.2–1.0)

0.0500

13

11

2.4 (1.0-5.0)

0.4904

Secondary outcome

Microvascular complications

46

25

1.4 (1.0–2.5)

0.1085

34

37

0.9 (0.5-1.7) 

0.7110

Macrovascular complications

20

5

2.6 (1.0–5.1)

0.0463

13

12

1.2 (0.6-2.7)

0.5810

 

The obesity was defined by as the definition of the criteria of Japan Society for the Study of Obesity. Body mass Index (BMI) with 25.0 kg/m2 was defined as obesity. The 400 patients in each group were classified as having obesity and hypertension or normotension according to values of blood pressure as recent guidelines show normotensions are less than 125 mm Hg measured in the home (HBP#) and less than 130 mmHg measured in the clinic (CBP##) at end-point, respectively. Differences in primary and secondary outcomes for events between obese patients with hypertension and normotension measured at end-point in each group were assessed using survival curves from the Kaplan-Meier method, and comparisons were analyzed using hazard ratio by the log-rank test. CI, confidence interval. Two-tailed values of P < 0.05 were defined as statistically significant.